Publicacións nas que colabora con Jaime Calvo Alén (56)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

2021

  1. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  2. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  3. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  4. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  5. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

  6. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  7. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  2. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  3. Bacteremia in systemic lupus erythematosus in patients from a Spanish registry: Risk factors, clinical and microbiological characteristics, and outcomes

    Journal of Rheumatology, Vol. 47, Núm. 2, pp. 234-240

  4. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377

  5. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)

    Lupus, Vol. 29, Núm. 1, pp. 27-36

  6. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  7. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review

    Reumatologia Clinica, Vol. 16, Núm. 3, pp. 222-228

  8. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281

  9. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224